XTL Biopharmaceuticals Ltd ADR (XTLB) — Net Asset Quality Index
XTL Biopharmaceuticals Ltd ADR (XTLB) has a Net Asset Quality Index of 63.6% as of March 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $8.55 Million minus total liabilities of $3.12 Million yields net assets of $5.43 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check XTLB financial resilience to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
XTL Biopharmaceuticals Ltd ADR Net Asset Quality Index Over Time (2002–2024)
This chart shows how XTL Biopharmaceuticals Ltd ADR's Net Asset Quality Index has evolved across 23 annual periods from 2002 to 2024. As of March 2025, the index stands at 63.6%, representing net assets of $5.43 Million against total assets of $8.55 Million USD. See XTLB working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for XTL Biopharmaceuticals Ltd ADR (2002–2024)
The table below presents the year-by-year Net Asset Quality Index for XTL Biopharmaceuticals Ltd ADR from 2002 to 2024, covering 23 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see XTLB market cap overview.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 63.6% | $5.43 Million | $8.55 Million | $3.12 Million | ▼ -27.9 pp |
| 2023 | 91.5% | $2.22 Million | $2.43 Million | $206.00K | ▼ -4.0 pp |
| 2022 | 95.5% | $4.00 Million | $4.19 Million | $187.00K | ▲ +14.9 pp |
| 2021 | 80.6% | $5.33 Million | $6.62 Million | $1.28 Million | ▼ -15.5 pp |
| 2020 | 96.1% | $6.25 Million | $6.50 Million | $254.00K | ▼ -0.7 pp |
| 2019 | 96.8% | $6.98 Million | $7.21 Million | $232.00K | ▼ -0.3 pp |
| 2018 | 97.0% | $8.32 Million | $8.57 Million | $253.00K | ▲ +42.1 pp |
| 2017 | 54.9% | $3.62 Million | $6.59 Million | $2.97 Million | ▼ -34.1 pp |
| 2016 | 89.1% | $2.69 Million | $3.02 Million | $330.00K | ▼ -2.7 pp |
| 2015 | 91.8% | $4.89 Million | $5.32 Million | $436.00K | ▲ +8.9 pp |
| 2014 | 82.9% | $4.68 Million | $5.64 Million | $965.00K | ▼ -1.8 pp |
| 2013 | 84.7% | $6.79 Million | $8.02 Million | $1.23 Million | ▼ -0.4 pp |
| 2012 | 85.0% | $9.42 Million | $11.09 Million | $1.66 Million | ▲ +0.5 pp |
| 2011 | 84.6% | $3.44 Million | $4.07 Million | $629.00K | ▲ +9.9 pp |
| 2010 | 74.6% | $2.83 Million | $3.80 Million | $963.00K | ▲ +73.7 pp |
| 2009 | 1.0% | $7.00K | $715.00K | $708.00K | ▼ -40.6 pp |
| 2008 | 41.6% | $1.43 Million | $3.43 Million | $2.00 Million | ▼ -19.0 pp |
| 2007 | 60.6% | $8.56 Million | $14.13 Million | $5.56 Million | ▼ -24.0 pp |
| 2006 | 84.6% | $22.76 Million | $26.90 Million | $4.14 Million | ▲ +10.3 pp |
| 2005 | 74.3% | $11.25 Million | $15.15 Million | $3.90 Million | ▼ -2.2 pp |
| 2004 | 76.5% | $19.60 Million | $25.62 Million | $6.02 Million | ▼ -6.4 pp |
| 2003 | 82.9% | $20.61 Million | $24.85 Million | $4.25 Million | ▼ -7.7 pp |
| 2002 | 90.6% | $34.83 Million | $38.42 Million | $3.59 Million | — |